Related Experiment Video
Updated: Nov 13, 2025
02:47
Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
Published on: May 12, 2023
1.7K
RNA therapeutics for cardiovascular disease
Christian Boada1,2, Roman Sukhovershin1, Roderic Pettigrew2,3
1RNA Therapeutics Program, Department of Cardiovascular Sciences, Houston Methodist Academic Institute.
Current Opinion in Cardiology
|March 12, 2021
Summary
RNA therapeutics, a rapidly advancing field, offers new ways to treat cardiovascular diseases by targeting specific genes. Nanotechnology is improving the delivery of these innovative RNA drugs currently in clinical trials.
Area of Science:
- RNA therapeutics
- Cardiovascular disease
- Gene targeting
Background:
- Messenger RNA (mRNA) vaccines have highlighted the potential of RNA-based therapeutics.
- RNA drugs function as biological software for rapid design and application.
- Cardiovascular disease presents numerous undruggable pathways amenable to RNA-based interventions.
Purpose of the Study:
- Review mechanisms of RNA-based drugs.
- Discuss applications in cardiovascular disease treatment.
- Focus on therapeutics in clinical trials and enabling nanotechnology.
Main Methods:
- Literature review of RNA therapeutics mechanisms.
- Analysis of RNA drug applications in cardiovascular disease.
- Examination of nanotechnology in RNA drug delivery.
Main Results:
- RNA utility is demonstrated for previously undruggable cardiovascular disease pathways.
- Nanotechnology has advanced RNA delivery challenges.
- Several RNA-based drugs for hypercholesterolemia and myocardial infarction are in clinical trials.
Conclusions:
- RNA therapeutics represent a versatile platform for addressing unmet medical needs.
- This field is rapidly emerging with significant potential.
- RNA therapeutics are poised to transform cardiovascular disease care standards.
Related Concept Videos
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
3.6K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.6K
01:27Coronary Artery Disease V: Interprofessional Care
115
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
115
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
946
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
946
01:26Atherosclerosis III: Management
110
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
110
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
660
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
660
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
308
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
308